$CRSP
CRISPR Therapeutics AG Stock $crsp

$crsp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024017571 Filed on February 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$504.0K	$201.2M	$371.2M
YoY Change	-99.5%	3353333.33%	30885.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$64.92M	$36.48M	$206.4M
YoY Change	0.57%	30.32%	-2.96%
% of Gross Profit
Research & Development	$76.17M	$95.14M	$387.3M
YoY Change	-23.78%	-8.12%	-16.1%
% of Gross Profit
Depreciation & Amortization	$4.833M	$4.937M	$19.84M
YoY Change	-4.32%	-15.55%	-17.93%
% of Gross Profit
Operating Expenses	$141.1M	$131.6M	$593.7M
YoY Change	-14.22%	0.06%	-11.95%
Operating Profit	-$140.6M		-$222.5M
YoY Change	118.01%		-66.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$24.72M	$20.00M	$71.82M
YoY Change	94.0%	74.04%	216.91%
Pretax Income	-$115.9M	$89.58M	-$150.7M
YoY Change	123.92%	-174.62%	-76.83%
Income Tax	$700.0K	$233.0K	$2.888M
% Of Pretax Income		0.26%
Net Earnings	-$116.6M	$89.35M	-$153.6M
YoY Change	119.71%	-180.8%	-76.37%
Net Earnings / Revenue	-23133.13%	44.41%	-41.38%
Basic Earnings Per Share	-$1.43		-$1.94
Diluted Earnings Per Share	-$1.43	$1.12	-$1.94
COMMON SHARES
Basic Shares Outstanding	80.28M	79.43M	79.22M
Diluted Shares Outstanding	81.79M		79.22M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.162B	$587.3M	$1.694B
YoY Change	91.19%	58.22%	-6.7%
Cash & Equivalents	$707.4M	$389.5M
Short-Term Investments	$455.0M	$197.8M	$1.304B
Other Short-Term Assets	$11.50M	$14.39M	$14.39M
YoY Change	-53.63%	-61.85%	-61.85%
Inventory
Prepaid Expenses
Receivables	$0.00	$200.0M	$200.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.120B	$1.908B	$1.908B
YoY Change	11.09%	2.97%	2.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$147.3M	$151.9M	$305.9M
YoY Change	-9.21%	-7.14%	-4.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$1.973M	$1.973M
YoY Change	-100.0%	-96.29%	-96.29%
Other Assets	$9.368M	$1.975M	$13.57M
YoY Change	239.42%	-57.44%	-16.65%
Total Long-Term Assets	$319.4M	$321.5M	$321.5M
YoY Change	-5.06%	-17.57%	-17.57%
TOTAL ASSETS
Total Short-Term Assets	$2.120B	$1.908B	$1.908B
Total Long-Term Assets	$319.4M	$321.5M	$321.5M
Total Assets	$2.439B	$2.230B	$2.230B
YoY Change	8.67%	-0.6%	-0.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.46M	$38.15M	$38.15M
YoY Change	-63.54%	39.08%	39.08%
Accrued Expenses	$76.43M	$45.34M	$60.96M
YoY Change	-10.74%	-41.64%	-34.82%
Deferred Revenue	$4.072M	$4.105M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$119.0M	$108.8M	$108.8M
YoY Change	-18.94%	-10.17%	-10.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.615M	$958.0K	$238.0M
YoY Change	-37.66%	-83.95%	-3.45%
Total Long-Term Liabilities	$3.615M	$958.0K	$238.0M
YoY Change	-37.66%	-83.95%	-3.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$119.0M	$108.8M	$108.8M
Total Long-Term Liabilities	$3.615M	$958.0K	$238.0M
Total Liabilities	$355.1M	$346.8M	$346.8M
YoY Change	-8.83%	-5.66%	-5.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.116B	-$999.7M
YoY Change	24.15%	18.15%
Common Stock	$3.202B	$2.881B
YoY Change	15.86%	5.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$62.00K	$62.00K
YoY Change	-1.59%	-1.59%
Treasury Stock Shares
Shareholders Equity	$2.084B	$1.883B	$1.883B
YoY Change
Total Liabilities & Shareholders Equity	$2.439B	$2.230B	$2.230B
YoY Change	8.67%	-0.6%	-0.6%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$116.6M	$89.35M	-$153.6M
YoY Change	119.71%	-180.8%	-76.37%
Depreciation, Depletion And Amortization	$4.833M	$4.937M	$19.84M
YoY Change	-4.32%	-15.55%	-17.93%
Cash From Operating Activities	$109.8M	-$96.07M	-$260.4M
YoY Change	1147.32%	-15.22%	-47.48%
INVESTING ACTIVITIES
Capital Expenditures	$721.0K	$770.0K	$9.470M
YoY Change	-76.43%	-87.56%	-74.53%
Acquisitions
YoY Change
Other Investing Activities	-$97.08M	-$80.68M	$386.6M
YoY Change	-180.3%	-52.35%	-274.57%
Cash From Investing Activities	-$97.80M	-$81.45M	$374.6M
YoY Change	-183.0%	-53.6%	-244.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$32.72M
YoY Change			3273.3%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	305.9M	38.96M	62.66M
YoY Change	5561.25%	1472.4%	62.38%
NET CHANGE
Cash From Operating Activities	109.8M	-96.07M	-260.4M
Cash From Investing Activities	-97.80M	-81.45M	374.6M
Cash From Financing Activities	305.9M	38.96M	62.66M
Net Change In Cash	317.9M	-138.6M	177.0M
YoY Change	140.7%	-51.62%	-124.73%
FREE CASH FLOW
Cash From Operating Activities	$109.8M	-$96.07M	-$260.4M
Capital Expenditures	$721.0K	$770.0K	$9.470M
Free Cash Flow	$109.0M	-$96.84M	-$269.8M
YoY Change	1799.49%	-18.97%	-49.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001674416
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37923
CY2023	dei	Entity Registrant Name EntityRegistrantName	CRISPR THERAPEUTICS AG
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	V8
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Baarerstrasse 14
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Zug
CY2023	dei	Entity Address Country EntityAddressCountry	CH
CY2023	dei	City Area Code CityAreaCode	41 (0)41
CY2023	dei	Local Phone Number LocalPhoneNumber	561 32 77
CY2023	dei	Security12b Title Security12bTitle	Common Shares, nominal value CHF 0.03
CY2023	dei	Trading Symbol TradingSymbol	CRSP
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4100000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80275950
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	389477000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211885000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1304215000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1603433000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	200000000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14386000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	37708000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1908078000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1853026000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	151945000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163634000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1973000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	53130000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	71000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11591000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11635000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	153993000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	156921000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1975000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4640000
CY2023Q4	us-gaap	Assets Assets	2229571000
CY2022Q4	us-gaap	Assets Assets	2243057000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	38147000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27428000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45335000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	77682000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4105000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	76162000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	102464000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	99690000
CY2023	crsp	Collaboration Expense CollaborationExpense	130250000
CY2022	crsp	Collaboration Expense CollaborationExpense	110250000
CY2021	crsp	Collaboration Expense CollaborationExpense	101178000
CY2023	us-gaap	Operating Expenses OperatingExpenses	593744000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	438000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	135000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15625000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15842000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5141000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	108791000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	121107000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	14012000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12323000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	223007000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	228179000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	958000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5969000
CY2023Q4	us-gaap	Liabilities Liabilities	346768000
CY2022Q4	us-gaap	Liabilities Liabilities	367578000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	126536183
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150347467
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80214694
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	78692766
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80044378
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	78512450
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2497000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2441000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	170316
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	180316
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	62000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	63000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2878155000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2734838000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-999700000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-846090000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1913000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15647000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1882803000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1875479000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2229571000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2243057000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	371206000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1198000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	914963000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	387332000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	461645000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	340567000
CY2022	us-gaap	Operating Expenses OperatingExpenses	674359000
CY2021	us-gaap	Operating Expenses OperatingExpenses	541435000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-222538000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-673161000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	373528000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71816000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22661000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6003000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71816000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22661000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6003000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-150722000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-650500000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	379531000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2888000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-325000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1870000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153610000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-650175000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	377661000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	73000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-80000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	17487000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10500000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4973000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-136050000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-660755000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	372677000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.36
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.97
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79220930
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77746575
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75948686
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.36
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.7
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79220930
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77746575
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80393496
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1664234000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	222175000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	15000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35874000
CY2021	crsp	Stock Purchased During Period Value Employee Stock Purchase Plan StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan	2095000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	102390000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4984000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	377661000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2399460000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	970000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	8000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35813000
CY2022	crsp	Stock Purchased During Period Value Employee Stock Purchase Plan StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan	2036000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	97947000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10580000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-650175000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1875479000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32394000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	10000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28103000
CY2023	crsp	Stock Purchased During Period Value Employee Stock Purchase Plan StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan	1839000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	81028000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	17560000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153610000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1882803000
CY2023	us-gaap	Profit Loss ProfitLoss	-153610000
CY2022	us-gaap	Profit Loss ProfitLoss	-650175000
CY2021	us-gaap	Profit Loss ProfitLoss	377661000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19837000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24172000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17953000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	81028000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	97947000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	102390000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	16545000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-12470000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-14109000
CY2023	crsp	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	2500000
CY2022	crsp	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0
CY2021	crsp	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	200000000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-305000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	161000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23219000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1598000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13912000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-20247000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5164000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	37514000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5794000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1011000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-783000
CY2023	crsp	Increase Decrease In Operating Lease Assets And Liabilities IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities	-2461000
CY2022	crsp	Increase Decrease In Operating Lease Assets And Liabilities IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities	15310000
CY2021	crsp	Increase Decrease In Operating Lease Assets And Liabilities IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities	9506000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	110000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1521000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5305000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-260375000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-495741000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	538972000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9470000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37188000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81705000
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	2500000
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1065911000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1417800000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1509327000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1452528000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1196333000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	555602000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	374647000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-258655000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1035430000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32721000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	970000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	213267000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	29943000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	37622000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	37678000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62664000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38592000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250945000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-80000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-11000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	177009000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-715884000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-245524000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	224060000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	939944000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1185468000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	401068000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	224060000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	939944000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	725000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2121000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8348000
CY2023	crsp	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	417000
CY2022	crsp	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	99000
CY2021	crsp	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	334000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	389477000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211885000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	923031000
CY2023Q4	us-gaap	Cash Collateral For Borrowed Securities CashCollateralForBorrowedSecurities	0
CY2022Q4	us-gaap	Cash Collateral For Borrowed Securities CashCollateralForBorrowedSecurities	540000
CY2021Q4	us-gaap	Cash Collateral For Borrowed Securities CashCollateralForBorrowedSecurities	0
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11591000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11635000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16913000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	401068000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	224060000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	939944000
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-10-31
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-999700000
CY2023Q4	crsp	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	1695700000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	389500000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211900000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	200000000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12300000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12300000
CY2023Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2022Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	197800000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	159300000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	191721000
CY2023Q4	crsp	Cash Equivalents Gross Unrealized Gains Before Tax CashEquivalentsGrossUnrealizedGainsBeforeTax	0
CY2023Q4	crsp	Cash Equivalents Gross Unrealized Losses Before Tax CashEquivalentsGrossUnrealizedLossesBeforeTax	0
CY2023Q4	crsp	Cash Equivalents Fair Value CashEquivalentsFairValue	191721000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1304304000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3821000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1937000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1306188000
CY2023Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	1496025000
CY2023Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax	3821000
CY2023Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax	1937000
CY2023Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Fair Value CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue	1497909000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	52592000
CY2022Q4	crsp	Cash Equivalents Gross Unrealized Gains Before Tax CashEquivalentsGrossUnrealizedGainsBeforeTax	0
CY2022Q4	crsp	Cash Equivalents Gross Unrealized Losses Before Tax CashEquivalentsGrossUnrealizedLossesBeforeTax	2000
CY2022Q4	crsp	Cash Equivalents Fair Value CashEquivalentsFairValue	52590000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1672164000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	626000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16227000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1656563000
CY2022Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	1724756000
CY2022Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax	626000
CY2022Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax	16229000
CY2022Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Fair Value CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue	1709153000
CY2023Q4	crsp	Debt Securities Available For Sale Unrealized Gain Position DebtSecuritiesAvailableForSaleUnrealizedGainPosition	1900000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	15600000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	463500000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	628400000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	138400000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	619200000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	2000000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	53100000
CY2023Q4	crsp	Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	205378000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	197466000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	53433000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33832000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	151945000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163634000
CY2023	us-gaap	Depreciation Depreciation	19800000
CY2022	us-gaap	Depreciation Depreciation	24100000
CY2021	us-gaap	Depreciation Depreciation	17900000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17347000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19241000
CY2023Q4	crsp	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	16962000
CY2022Q4	crsp	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	35010000
CY2023Q4	crsp	Accrued Collaboration Costs AccruedCollaborationCosts	2395000
CY2022Q4	crsp	Accrued Collaboration Costs AccruedCollaborationCosts	11177000
CY2023Q4	crsp	Accrued License Fees Current AccruedLicenseFeesCurrent	3143000
CY2022Q4	crsp	Accrued License Fees Current AccruedLicenseFeesCurrent	983000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2515000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4927000
CY2023Q4	crsp	Accrued Intellectual Property Costs Current AccruedIntellectualPropertyCostsCurrent	1642000
CY2022Q4	crsp	Accrued Intellectual Property Costs Current AccruedIntellectualPropertyCostsCurrent	3936000
CY2023Q4	crsp	Accrued Property And Equipment AccruedPropertyAndEquipment	630000
CY2022Q4	crsp	Accrued Property And Equipment AccruedPropertyAndEquipment	1244000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	701000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1164000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45335000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	77682000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	153993000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	156921000
CY2023Q4	crsp	Lease Assets LeaseAssets	153993000
CY2022Q4	crsp	Lease Assets LeaseAssets	156921000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15625000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15842000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	223007000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	228179000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	238632000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	244021000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	25870000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	34896000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	22520000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	824000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11087000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	14387000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	11882000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	8402000
CY2023	us-gaap	Sublease Income SubleaseIncome	137000
CY2022	us-gaap	Sublease Income SubleaseIncome	0
CY2021	us-gaap	Sublease Income SubleaseIncome	5253000
CY2023	us-gaap	Lease Cost LeaseCost	40120000
CY2022	us-gaap	Lease Cost LeaseCost	47602000
CY2021	us-gaap	Lease Cost LeaseCost	36756000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	28703000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28825000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	29402000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	28669000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	28146000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	178884000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	322629000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83997000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	238632000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.059
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.059
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	115681000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13900000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	27310000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	17004000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	19753000
CY2023	crsp	Right Of Use Assets Increased Through Lease Modifications And Reassessments RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments	2660000
CY2022	crsp	Right Of Use Assets Increased Through Lease Modifications And Reassessments RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments	1208000
CY2021	crsp	Right Of Use Assets Increased Through Lease Modifications And Reassessments RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments	-14230000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7552000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	152486000
CY2023	crsp	Leasehold Improvements Paid Directly By Landlord LeaseholdImprovementsPaidDirectlyByLandlord	0
CY2022	crsp	Leasehold Improvements Paid Directly By Landlord LeaseholdImprovementsPaidDirectlyByLandlord	19252000
CY2021	crsp	Leasehold Improvements Paid Directly By Landlord LeaseholdImprovementsPaidDirectlyByLandlord	30500000
CY2022	crsp	Accounting Analysis Defer Option Specified Cost AccountingAnalysisDeferOptionSpecifiedCost	110300000
CY2023	crsp	Accounting Analysis Defer Option Specified Cost AccountingAnalysisDeferOptionSpecifiedCost	110300000
CY2023	crsp	Deferred Finance Costs Share Lending Arrangement Issuance Costs DeferredFinanceCostsShareLendingArrangementIssuanceCosts	80900000
CY2022	crsp	Deferred Finance Costs Share Lending Arrangement Issuance Costs DeferredFinanceCostsShareLendingArrangementIssuanceCosts	36100000
CY2023	crsp	Accounting Analysis Defer Option Amount AccountingAnalysisDeferOptionAmount	0
CY2022	crsp	Accounting Analysis Defer Option Amount AccountingAnalysisDeferOptionAmount	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2023Q4	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	20989313
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote for each common share
CY2023	us-gaap	Dividends Dividends	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81000000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	97900000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	102400000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7204372
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	55.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115681000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4861029
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	53.73
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81028000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	97947000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	102390000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	80300000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	72000000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1860485
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1492589
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1616255
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	45.47
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	60.19
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	124.32
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	28.39
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	38.54
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	77.38
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.651
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.702
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.703
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.041
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.026
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7230233
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	60.22
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	32131000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1860485
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	45.47
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	742291
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	38.53
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1144055
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	82.84
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	88206000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7204372
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	55.05
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	40800000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	119500000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153610000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-650175000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	377661000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79220930
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77746575
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75948686
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79220930
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77746575
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80393496
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.36
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.97
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.36
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.7
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9001813
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8574523
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1998456
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3000000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3200000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3400000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	30357000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1321000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	4569000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-181079000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-651821000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	374962000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-150722000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-650500000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	379531000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2318000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	444000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	80000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	994000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	241000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	42000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3312000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	685000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	122000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-424000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1010000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1748000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-424000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1010000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1748000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2888000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-325000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1870000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.006
CY2023	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0
CY2022	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0
CY2021	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.04
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.025
CY2023	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	0.001
CY2022	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	-0.001
CY2021	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.082
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.033
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.042
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.172
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.158
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.05
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.019
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	133384000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	118432000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4485000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4782000
CY2023Q4	crsp	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	65177000
CY2022Q4	crsp	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	66436000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15987000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10154000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18346000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18034000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	70404000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	63416000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	307783000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	281254000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	227615000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	198279000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	80168000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	82975000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	38725000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	41206000
CY2023Q4	crsp	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	42058000
CY2022Q4	crsp	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	42678000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	18000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	209000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	80787000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	84111000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	619000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1136000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	29300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	2223300000
CY2023	crsp	Operating Loss Carryforwards Expiration Period OperatingLossCarryforwardsExpirationPeriod	2027
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	44100000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	40100000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2022Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2021Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	34536000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21395000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11967000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	9703000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	10439000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	9911000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2702000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	91000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	483000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	44148000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	34536000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21395000

Files In Submission

Name	View Source	Status
0000950170-24-017571-index-headers.html	Edgar Link	pending
0000950170-24-017571-index.html	Edgar Link	pending
0000950170-24-017571.txt	Edgar Link	pending
0000950170-24-017571-xbrl.zip	Edgar Link	pending
crsp-20231231.htm	Edgar Link	pending
crsp-20231231.xsd	Edgar Link	pending
crsp-ex21_1.htm	Edgar Link	pending
crsp-ex23_1.htm	Edgar Link	pending
crsp-ex31_1.htm	Edgar Link	pending
crsp-ex31_2.htm	Edgar Link	pending
crsp-ex32_1.htm	Edgar Link	pending
crsp-ex4_1.htm	Edgar Link	pending
crsp-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img133321815_0.jpg	Edgar Link	pending
img168450911_0.jpg	Edgar Link	pending
img168450911_1.jpg	Edgar Link	pending
img168450911_10.jpg	Edgar Link	pending
img168450911_11.jpg	Edgar Link	pending
img168450911_12.jpg	Edgar Link	pending
img168450911_13.jpg	Edgar Link	pending
img168450911_14.jpg	Edgar Link	pending
img168450911_2.jpg	Edgar Link	pending
img168450911_3.jpg	Edgar Link	pending
img168450911_4.jpg	Edgar Link	pending
img168450911_5.jpg	Edgar Link	pending
img168450911_6.jpg	Edgar Link	pending
img168450911_7.jpg	Edgar Link	pending
img168450911_8.jpg	Edgar Link	pending
img168450911_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
crsp-20231231_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRSP
CRISPR Therapeutics AG Stock $crsp

2024 Q1 Form 10-K Financial Statement

#000095017024017571 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRSP CRISPR Therapeutics AG Stock $crsp

2024 Q1 Form 10-K Financial Statement

#000095017024017571 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRSP
CRISPR Therapeutics AG Stock $crsp